Effectiveness of Empagliflozin Use in Patients with Diabetes Mellitus Type 2
Oksana Didushko,
Published on: 2020-08-03
Abstract
It has been proved the effectiveness of empagliflozin use in preventing the key cardiovascular risk factors in patients with diabetes mellitus type 2, with normal weight and overweight, who had gotten metformin. An SGLT2 inhibitor empagliflozin decreases statistically body weight in patients with overweight and decreases statistically carbohydrate metabolism indices, systolic blood pressure, as well as leptin level in patients with normal weight and overweight.
